Company / Cash & Equivalents
RadNet, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$767.2M
FY2025
5-year range
$127.8M / $767.2M
FY2021-FY2025
Trend
+3.7%
vs FY2024
Sector context
#37 of 152
Health Care
What the data says
RadNet, Inc.'s cash & equivalents of $767M is higher than 76% of companies in the Health Care sector (FY2025). Cash & Equivalents has increased for 3 consecutive years, from $128M in FY2022 to $767M in FY2025.
Based on SEC 10-K filings.
$767M in FY2025 with a 5-year CAGR of +49.7%. Top quartile in the Health Care sector.
Improved from $343M to $767M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +81.7%
- 5-Year CAGR
- +49.7%
- 10-Year CAGR
- -
Sector benchmark
-34.1% below sector average
Key checks
Key Insights
- RadNet, Inc.'s cash & equivalents has grown for 3 consecutive years.
- 5-year CAGR of +49.7%, indicating consistent growth.
- In FY2025, cash & equivalents increased 3.7% year-over-year.
- Ranks #37 out of 152 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $767.2M | +3.7% |
| FY2024 | $740.0M | +116.0% |
| FY2023 | $342.6M | +168.0% |
| FY2022 | $127.8M | -5.0% |
| FY2021 | $134.6M | +31.9% |
| FY2020 | $102.0M | +154.0% |
| FY2019 | $40.2M | +286.6% |
| FY2018 | $10.4M | -79.8% |
| FY2017 | $51.3M | +148.7% |
| FY2016 | $20.6M | +4527.4% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026